Hier finden Sie wissenschaftliche Publikationen aus den Fraunhofer-Instituten.

Clot-Derived Contaminants in Transplanted Bone Marrow Mononuclear Cells Impair the Therapeutic Effect in Stroke

: Okinaka, Y.; Kikuchi-Taura, A.; Takeuchi, Y.; Ogawa, Y.; Boltze, J.; Gul, S.; Claussen, C.; Taguchi, A.


Stroke 50 (2019), No.10, pp.2883-2891
ISSN: 0039-2499
ISSN: 0749-7954
ISSN: 1524-4628
Bundesministerium für Bildung und Forschung BMBF (Deutschland)
Journal Article
Fraunhofer IME ()

Background and Purpose. The beneficial effects of bone marrow mononuclear cell (BM-MNC) transplantation in preclinical experimental stroke have been reliably demonstrated. However, only overall modest effects in clinical trials were observed. We have investigated and reported a cause of the discrepancy between the preclinical and clinical studies. Methods. To investigate the possible cause of low efficacy of BM-MNC transplantation in experimental stroke, we have focused on blood clot formation, which is not uncommon in human bone marrow aspirates. To evaluate the effects of clot-derived contaminants in transplanted BM-MNC on stroke outcome, a murine stroke model was used. Results. We show that BM-MNC separated by an automatic cell isolator (Sepax2), which does not have the ability to remove clots, did not attenuate brain atrophy after stroke. In contrast, manually isolated, clot-free BM-MNC exerted therapeutic effects. Clot-derived contaminants were also transplanted intravenously to poststroke mice. We found that the transplanted contaminants were trapped at the peristroke area, which were associated with microglial/macrophage activation. Conclusions. Clot-derived contaminants in transplanted BM-MNC nullify therapeutic effects in experimental stroke. This may explain neutral results in clinical trials, especially in those using automated stem cell separators that lack the ability to remove clot-derived contaminants.